Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FZ201
- Development stage
- Preclinical
- Lead developer
- FZata
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
FZ201 is a preclinical-stage live biotherapeutic product being developed by Fzata for the treatment and prevention of *Clostridioides difficile* infection (CDI). Utilizing Fzata's proprietary BioPYM (Biologic-Producing Yeast Micro-medicine) platform, FZ201 consists of a live probiotic yeast engineered to express and secrete therapeutic proteins directly in the gastrointestinal tract. The drug is designed to neutralize *C. difficile* toxins (TcdA and TcdB) and inhibit pathogen colonization, providing a dual-action approach to managing CDI. Administered orally, FZ201 aims to provide a localized, sustained therapeutic effect while maintaining a favorable safety profile compared to systemic treatments.
- Other names
- FZ201FZ-201FZ 201
02
Targets
TcdA (Clostridioides difficile toxin A)TcdB (Clostridioides difficile large clostridial toxin family)
Beyond the preview
Go deeper on FZ201.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on FZ201.